Cetuximab & Panitumumab
Erbitux · Vectibix · Anti-EGFR antibody
TRPM6 magnesium wasting.
LYTE
MildOpen →
Gamma-secretase inhibitor
Nirogacestat
Ogsiveo · Niro
A gamma-secretase inhibitor for desmoid tumors — watch phosphate and electrolytes.
MildGamma-secretase inhibitor · approved 2023
Desmoid tumors (aggressive fibromatosis)
Signature kidney injury
Electrolyte Wasting
Electrolyte and phosphate disturbances (including hypophosphatemia) are reported among adverse events; the characteristic DeFi-trial toxicities were diarrhea, rash, nausea, fatigue and ovarian dysfunction. Renal-specific incidence is not well quantified.
Source: Gounder et al., N Engl J Med 2023 (DeFi)
Mechanism of kidney injury
Gamma-secretase/Notch signaling participates in epithelial differentiation and mineral/phosphate homeostasis; its inhibition is postulated to perturb proximal-tubular electrolyte and phosphate handling, producing hypophosphatemia and other electrolyte shifts (a partial proximal-tubular/Fanconi-like phenotype is the conceptual concern). Robust nephron-level human data are lacking, so characterization is conservative and class/electrolyte-based rather than tied to a defined tubular lesion. Diarrhea-related volume/electrolyte loss can compound the picture.
Clinical presentation
Hypophosphatemia and other electrolyte abnormalities on labs; if a proximal-tubular pattern occurs, low phosphate with phosphaturia and possibly glucosuria/aminoaciduria. Serum creatinine is usually preserved.
Onset
During therapy; not well characterized.
Reversibility
Reversible
Anticancer mechanism
Oral gamma-secretase inhibitor that blocks the regulated intramembrane proteolysis of Notch (and other gamma-secretase substrates), preventing release of the Notch intracellular domain and downstream transcription. In desmoid tumors (aggressive fibromatosis), Notch-pathway suppression drives the antitumor effect.
Management
Electrolyte and phosphate repletion; supportive care for diarrhea-related losses; dose interruption/modification per label for significant toxicity. No specific renal antidote; abnormalities are generally reversible.
Risk factors
- Baseline electrolyte/phosphate disturbance
- Concurrent diarrhea/volume loss
- Pre-existing CKD
- Poor oral intake
Prevention
- Monitor phosphate and electrolytes periodically
- Oral phosphate/electrolyte repletion as needed
- Hydration during diarrhea
- Address contributing GI toxicity early
Note · Renal involvement is limited to electrolyte/phosphate disturbance; there is no established intrinsic nephrotoxic lesion. The phosphate signal warrants periodic monitoring even though a defined Fanconi syndrome has not been characterized for this agent.
Clinical depth
Renal dose adjustment
No established renal dose adjustment; not studied in significant renal impairment. Modify dose for GI/dermatologic toxicity per label rather than for GFR. CYP3A interactions apply.
Dialyzability & ESKD dosing
Hepatically metabolized small molecule; dialyzability not characterized and not the management focus. In advanced CKD, monitor and replete electrolytes/phosphate.
Differential diagnosis
Drug-related hypophosphatemia/electrolyte shift vs diarrhea-driven losses vs a true proximal-tubular (Fanconi) pattern (which would add glucosuria/aminoaciduria/normoglycemic phosphaturia); urine studies clarify if creatinine or phosphate handling is unexpectedly abnormal.
Monitoring
- Serum phosphate, potassium, magnesium and bicarbonate periodically
- Creatinine each cycle
- Hydration/stool frequency during diarrhea
Key trials & series
- DeFi (Gounder NEJM 2023) phase III in progressing desmoid tumors
Clinical pearls
- Monitor phosphate — hypophosphatemia is the most consistent renal-relevant lab finding with this gamma-secretase inhibitor.
- There is no defined nephrotoxic lesion; the kidney shows up as electrolyte/phosphate disturbance, often reversible with repletion.
- Diarrhea is common — distinguish GI-driven electrolyte loss from a primary tubular effect.
- Ovarian dysfunction and skin/GI toxicity dominate the overall profile; renal issues are secondary.
Where it strikes
Nephron segments
Proximal Tubule
Bulk reabsorption + drug uptake (OCT2, OATs)
Injury signatures
Electrolyte WastingFanconi Syndrome
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkNirogacestat, a gamma-Secretase Inhibitor for Desmoid Tumors.Gounder M et al. · N Engl J Med 2023 · PMID 36884323Pivotal DeFi trial describing the adverse-event profile including electrolyte/phosphate disturbances.PMIDConventional Chemotherapy Nephrotoxicity.Gupta S et al. · Adv Chronic Kidney Dis 2021 · PMID 35190107Onconephrology reference for drug-related electrolyte and proximal-tubular disturbances.PMIDExamining nirogacestat for adults with progressing desmoid tumors who require systemic treatment.Campos F et al. · Expert Opin Pharmacother 2024 · PMID 39414771Review of nirogacestat mechanism (NOTCH/gamma-secretase), pharmacology and toxicity, noting need for long-term safety data.PMIDRenal Side Effects of Novel Molecular Targeted Oncologic Agents.Fenoglio R et al. · G Ital Nefrol 2023 · PMID 38007829Onconephrology overview of renal effects of novel targeted agents, including delayed/under-recognized electrolyte and tubular effects.PMIDAdverse kidney effects of epidermal growth factor receptor inhibitors.Izzedine H et al. · Nephrol Dial Transplant 2017 · PMID 28339780Model of targeted-agent tubular electrolyte/phosphate wasting, a useful comparator for the gamma-secretase electrolyte signal.PMIDCurrent Trends in Anti-Cancer Molecular Targeted Therapies: Renal Complications and Their Histological Features.Tonooka A et al. · J Nippon Med Sch 2021 · PMID 34840210Histologic survey of targeted-therapy renal complications, framing the absence of a defined gamma-secretase-inhibitor lesion.